Administration of human leukocyte interferon to patients with subacute sclerosing panencephalitis

Yoshioka, Hiroshi; Nishimura, Osamu; Nakagawa, Masao; Ochi, Masaharu; Takeuchi, Yoshihiro; Tominaga, Masashi; Hasegawa, Kou; Osamura, Toshio; Goma, Hideyo; Sawada, Tadashi; Imanishi, Jirô

doi:10.1016/s0387-7604(89)80057-9

Cited by 18 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alpha-interferon was another drug that has been reported effective in SSPE [75]. Initially alpha-interferon was administered by intramuscular, intravenous or intrathecal routes.…”

Section: Treatmentmentioning

confidence: 99%

Subacute sclerosing panencephalitis

2008

View full text Add to dashboard Cite

Subacute sclerosing panencephalitis (SSPE) is a subacute encephalopathy of childhood and young adolescence. Infrequently, SSPE can occur in adults and pregnant women. It is caused by an aberrant measles virus, known as the SSPE virus. SSPE virus differs from wild-type measles viruses in the form of several mutations affecting the viral genome. The matrix gene is most commonly affected by these mutations. The characteristic clinical manifestations of SSPE include behavioral changes, cognitive decline, myoclonic jerks, seizures, abnormalities in vision, bilateral pyramidal signs and coma. Ocular changes may occur in up to 50% of patients. The most characteristic ophthalmological lesion is necrotizing retinitis. Cortical blindness can be the early feature of SSPE. The diagnosis of SSPE is often difficult in the early stages. In a typical case diagnosis is based on clinical, electroencephalographic, and cerebrospinal fluid findings. At present, there is no effective treatment to completely cure SSPE. Oral isoprinosine and intrathecal or intraventricular alpha-interferon may prolong survival to some extent. Immunization against measles is currently the most effective strategy against SSPE.

show abstract

“…Alpha-interferon was another drug that has been reported effective in SSPE [75]. Initially alpha-interferon was administered by intramuscular, intravenous or intrathecal routes.…”

Section: Treatmentmentioning

confidence: 99%

Subacute sclerosing panencephalitis

2008

View full text Add to dashboard Cite

show abstract

“…12,13 Alpha interferon is also used for the management of SSPE. 14 It is given via intraventricular route. Some studies suggest that even beta interferon can be used as a management option.…”

Section: Diagnosis Of Sspementioning

confidence: 99%

Ocular manifestations in subacute sclerosing panencephalitis

Sahu¹,

Chaudhary²,

Singh³

et al. 2019

IJCEO

View full text Add to dashboard Cite

Subacute sclerosing panencephalitis is a neurological disorder that leads to progressive neuronal damage caused by persistent measles virus. The usual age of onset of the disease is in childhood between the age of 10 to 14 years. Ocular manifestations are seen in 10 to 50% of the patients of SSPE. Common ocular findings include optic neuritis, papilledema, papillitis, optic atrophy, macular chorioretinitis, cortical blindness. Ophthalmic findings may occur along with or may sometimes precede the neurological involvement by few years. There is higher incidence in rural population, children with lower birth order, having 2 or more siblings. SSPE is twice as common in boys as in girls. Initial presentation starts as mild behavioral changes, progressing to specific motor and neurological disturbances in the form of myoclonic jerks, motor disturbances leading to involuntary muscle contractions, gait abnormalities, speech changes, pyramidal and extrapyramidal signs, amnesia, generalized tonic clonic seizures and partial seizures. Macular retinochoroiditis is the most common ocular finding in SSPE. The diagnosis is based upon characteristic clinical manifestations, the presence of characteristic periodic slow wave complexes in EEG, and presence of increased antibody titre against measles virus in the plasma and cerebrospinal fluid (three out of five criteria given by Dyken are fulfilled). Treatment for SSPE is still undetermined. Various drug combination therapies have been used for the treatment of SSPE. Isoprinosine was the first drug reported to be effective against SSPE due to its immunomodulatory effects. Alpha interferon is also used for the management of SSPE. Studies suggest that even beta interferon can be used as a management option. Ribavirin, an antiviral drug, is effective against many RNA viruses.

show abstract

Apparent response of subacute sclerosing panencephalitis to intrathecal interferon alpha

Miyazaki

Hashimoto

Fujino

et al. 1991

Annals of Neurology

View full text Add to dashboard Cite

Another possibility is that the Ts16 neurons are developmentally immature relative to diploid neurons and that the rapidity of infection is a function of developmental maturity. Neonatal mice inoculated with scrapie prions intraperitoneally but not intracerebrally exhibited a prolongation of their incubation period {GI. Recently, there have been reports of successful treatment of SSPE with systemic 141, intrathecal 157, or intraventricular {b} administration of human interferon From the

show abstract

Administration of human leukocyte interferon to patients with subacute sclerosing panencephalitis

Cited by 18 publications

References 16 publications

Subacute sclerosing panencephalitis

Subacute sclerosing panencephalitis

Ocular manifestations in subacute sclerosing panencephalitis

Apparent response of subacute sclerosing panencephalitis to intrathecal interferon alpha

Contact Info

Product

Resources

About